254
Views
3
CrossRef citations to date
0
Altmetric
Review

Cardiovascular Disease-Associated Skin Conditions

& ORCID Icon
Pages 43-53 | Published online: 16 Feb 2022

Abstract

According to data from the American Heart Association and the World Health Organization, cardiovascular disease (CVD) is the most frequent cause of premature death. Several inflammatory and non-inflammatory skin diseases have been associated with metabolic syndrome and cardiovascular risk (CVR). Here, we classified these conditions into traditionally CVR-associated and those that have been linked to a lesser degree. Psoriasis and hidradenitis suppurativa are commonly associated with CVD, sharing common inflammatory pathways and a higher prevalence of traditional cardiovascular risk factors. Many other diseases could be associated indirectly – with no common pathogenic features with the atheromatous disease – but share a higher prevalence of standard cardiovascular risk and chronic inflammatory state. This review aims to highlight the associated cardiovascular risk that exists for some dermatologic diseases and sensitize cardiologists, dermatologists, and first care providers to implement risk factor control promptly.

Introduction

According to data from the American Heart Association and World Health Organization, cardiovascular disease (CVD) is the most frequent cause of premature death. Incidence and prevalence are rising.Citation1 Traditional risk factors such as increased systolic pressure, low HDL cholesterol, diabetes, and smoking are used to calculate the 10-year risk for cardiovascular events (CVE) with specially designed scales. Also, non-traditional risk factors have been proven to predict CVE even when they are not included in those specific scales like Carotid intima-media Thickness (cIMT) and homocysteine levelsCitation2 Several inflammatory and non-inflammatory skin diseases have been associated with metabolic syndrome, and some of this traditional or non-traditional cardiovascular-risk (CVR) factors.Citation3Citation5 Historically, psoriasis has been the most studied and accepted condition with increased CVR prompting dedicated study and active recommendations from dermatologists to patients to prevent CVE.Citation6 Hidradenitis suppurativa and atopic dermatitis have also been linked to CVE; nevertheless, many other inflammatory and non-inflammatory diseases are also directly or indirectly associated with CVR in terms of its etiopathogenesis. Herein, we present a comprehensive and concise description of prevalent skin diseases associated, to different degrees, with a higher CVR, pointing out shared features with atheromatosis. If these pathophysiological similarities are taken into account, better prevention strategies can be planned. We classified skin diseases into those with evidence of common pathogenic features with CVD – namely directly related diseases – and those that have increased traditional cardiovascular risk factors and chronic inflammation, named indirectly related diseases ().

Table 1 Broad Characteristics of Skin Diseases According to Cardiovascular Risk Association

Traditionally CVD-Associated Skin Diseases

These diseases have been thoroughly studied and related to increased CVR, and the condition shares pathophysiological mechanisms with CVD.

Psoriasis

Psoriasis is a chronic systemic inflammatory disorder that can present with or without articular involvement during its course.Citation7 Recently, psoriasis has been frequently associated with several inflammatory and non-inflammatory comorbidities. CVE and diabetes mellitus 2 are the top causes of mortality in these patients.Citation8 The relationship between CVR and psoriasis is linked mainly through a higher prevalence of traditional CVR factors like obesity and diabetes.Citation9 Since poorly controlled diabetes favors flares-up of psoriasis, both conditions have been proposed to have a common pathway of immune-mediated features.Citation6 Activation of 3 specific pathways has been associated with this matter through the pro-inflammatory role of the adipose tissue.Citation10 Both psoriasis and psoriatic arthritis are linked to CVR and CVE through three main elements: a chronic inflammatory state that stimulates atheroma plaque formation,Citation11 typical serum and local activated pathways,Citation6 and increased traditional and non-traditional CVR factors, all explained below.Citation12

Psoriasis and psoriatic arthritis are directly related to CVR.Citation13 Besides unspecific chronic inflammation, the axis IL-12/Th1 and IL-23/Th17 have been described as part of common immunological mechanisms leading to skin and endovascular plaque formation.Citation12 A decrease in peripheric regulatory T lymphocytes allows proliferation and activation of Th1 and Th17 lymphocytes with higher endovascular activity promoting pro-angiogenic and innate immune cell recruiting to the plaque.Citation10 It has been shown that patients with carotid atherosclerosis have higher serum levels of IL-23 than healthy controls. Also, carotid plaques of surgically treated patients showed higher IL-23 and IL-23R mRNA levels than control group.Citation14 The plaque is mainly formed because of the active participation of monocytes and macrophages, which are crucial to its development and expansion.Citation15 Monocytes are recruited to the plaque and then differentiate to foam cells phagocyting oxidated LDL cholesterol and producing cytokines and chemokines that favor changes in the microenvironment leading to the matrix and neo-intima formation.Citation16 Circulating inflammatory monocytes (called M1) have been shown to correlate with CVE;Citation17 moreover, M1 are active cells producing IL-23 suggesting that an M1-predominating setting could raise circulating IL-23 levels.Citation18 Traditional CVR factors like obesity, hypertension, and diabetes are also markedly prevalent in psoriatic patients and grow in severity with the disease.Citation10 Obese patients have a chronic low-grade inflammatory state that favors the production of pro-inflammatory peptides.Citation19

Interestingly, higher serum levels of IL-23 and IL-12 in obese patients have been reported, supporting shared pathogenic processes.Citation20 Adipokines are a particular mediator that participates both in the skin and articular involvement of the disease and in metabolic dysregulation, including insulin resistance and non-alcoholic fatty liver disease.Citation21 Arterial hypertension has been reported with odds ratios (OR) of 1.58,Citation9 with psoriatic patients being almost 20 times more likely to use three or more anti-hypertensive drugs than non-psoriatic patients.Citation22 Finally, there is a higher risk of diabetes and insulin resistance, and psoriatic patients are more prone to use antidiabetic drugs.Citation9 It has been postulated that the difficulty in achieving well-controlled diabetes is related to immunological effects of Th1 and Th17-produced cytokines.Citation23

With the advent of biological drugs, there is a new dimension to take into account regarding CVR in psoriasis.Citation24 Briefly, anti-TNFα agents seem to exert a positive effect on CVR as observed in relation to reduction in risk of myocardial infarction when compared to topical treatmentCitation25 or to methotrexateCitation26 whereas the effect of anti-IL17 and anti-IL12/23 drugs is less clear. The CVD effects anti-IL-17 drugs are controversial because the latter can exert pro or anti-atherogenic effects depending on the cellular, tissue, and immune context.Citation27 Nonetheless, there are new findings showing secukinumab might have a beneficial impact on CVR by improving the endothelial function of patients with psoriasis,Citation28 which contrasts with a cohort study that shows a higher risk of CVE in psoriatic patients that initiate an anti-IL-17 versus an anti-TNF drug.Citation29 More studies are warranted on this subject. The effect of anti-IL12/23 drugs is unclear, although it seems to be that there is a significant association between initiation of ustekinumab and the occurrence of a severe CVE in patients with high CV risk. No association was found in low CV risk patients.Citation30 In a cohort study, there was a significantly higher CVE risk in patients initiating an anti IL-12/23 versus an anti-TNF drug,Citation29 however, larger studies and studies aimed to explain the pathophysiologic mechanisms of this increased risk are needed.

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic suppurative inflammatory skin disease affecting apocrine gland-bearing intertriginous areas. Its prevalence varies widely between 0.03% and 8% depending mainly on the classification methodology usedCitation31,Citation32 Crohn’s disease and spondylarthritis have a higher prevalence of HS; therefore, metabolic features associated with these diseases are also shared with HS.Citation33

Many cardiac parameters underlying CVE have been found altered in HS patients: Heart rate and QRS duration are higher and shorter, respectively, features commonly found in CVE patients. These variables also correlate directly with cIMT values, which also are increased.Citation34 IL-32 levels are higher both in serum and lesions of HS patients. IL-32 is found to be higher in tissue after myocardial infarction, and its serum levels are inversely correlated with the prognosis of cardiac failure after CVE.Citation35 Interestingly, IL-32 is not a traditional inflammatory cytokine but an angiogenic stimulator and metalloproteinase activator, which are essential pathogenic features of atheromatous plaque growth.Citation36

The influence of the metabolic state in progression and response to treatment in HS patients is widely accepted.Citation37 Diabetes, a coronary risk equivalent of CVD, has been strongly associated with HS, with an OR of 1.69 for diabetes mellitus 2.Citation38 Systematically analyzed CVR factors in HS patients found that obesity and central obesity had a significant association with HS and active and non-active smoking, hypertriglyceridemia, low HDL, diabetes, and metabolic syndrome.Citation39 Even when the odds ratio ranged from 2 to 6, causality could not be assessed.Citation39 In another study, carotid intima-media thickness (cIMT), and accepted non-traditional CVR factor and marker of early atheromatosis, has been studied in HS patients. When analyzed versus age and sex-matched healthy controls, HS patients had significantly higher cIMT suggesting a more active atheromatous disease versus controls.Citation40 The analysis of almost 6000 patients was able to demonstrate that HS patients had an Incidence Risk Ratio (IRR) of 1.57 for myocardial infarction adjusted for modifiable and non-modifiable risk factors.Citation37 HS has been associated with a higher incidence of spondylarthritis, inflammatory bowel disease (IBD), and psoriasis, diseases previously associated with increased CVR due to a higher incidence of CVR factors and systemic inflammation.Citation41 In a small study, using Assessment of SpondyloArthritis international Society (ASAS) criteria, an OR of 11 for spondyloarthritis was found, being axial the most prevalent form.Citation33 In 2019, in a meta-analysis of 8 studies, a higher prevalence of IBD with OR ranging from 2 to 10 was found, showing a well-founded association between both conditions.Citation41 Spondylarthritis and IBD have been associated with CVR, supporting the relation between HS and CVR in the presence of companion diseases already associated with CVE.Citation42

Emergent CVD-Associated Skin Diseases

In this section, diseases that have been recently related to CVD are presented. These conditions share a plausible common pathophysiologic mechanism with CVD but lack the acumen of knowledge that the former conditions have.

Rosacea

Rosacea is an inflammatory disease affecting 5% to 6% of the population.Citation43 It is characterized by chronic erythema, papules, pustules, telangiectasia, affecting mainly centrofacial and ocular areas.Citation44 Its etiopathogenesis is complex with a broad interplay of influences, including immune, vascular and infectious, plus environmental factors such as UV light and alcohol consumption.Citation45 Many comorbidities have been associated with rosacea, including a higher incidence of CVE.Citation46 There is no consensus about whether this relation is actual comorbidity or just the coexistence between two prevalent diseases.Citation46

A possible explanation for those who advocate that rosacea has higher CVR is that pro-atherogenic vascular changes and inflammatory pathways are coincidental at some points.Citation47 Vascular endothelial growth factor (VEGF) has been associated with inflammation and vascular permeability. In rosacea, the prevalence of a specific +405C/G polymorphism of VEGF is increased by 1.7-fold.Citation48 This same polymorphism has been described in systemic inflammatory conditions widely associated with higher CVR like rheumatoid arthritis.Citation49 Moreover, higher VEGF levels have been found when metabolic risk factors like high body mass index (BMI) and smoking are present.Citation48 When Framingham Risk Score (FRS) or European CVR (SCORE) are applied to rosacea, no risk increase was found even when systolic blood pressure (SBP) and reactive C Protein (CRP) show higher levels in this group of patients.Citation50

In the formation of the atheromatous plaque, macrophages and monocytes are essential and participate actively in the expansion of the plaque and cytokine microenvironment.Citation51 Cathelicidins are innate immune cell-produced proteins that participate as defensins in response to infections.Citation52 These peptides are overexpressed in rosacea lesions versus healthy skin in the same subject.Citation44 Moreover, atheromatous plaque-infiltrating macrophages also overexpressed this protein, suggesting that they could be part of the same pathogenic process.Citation53 Also, since D.folliculorum and S.aureus are well-known agents in rosacea etiopathogenesis, their relation with LL-37 (cathelicidin microbial peptide) and kallikrein-5 production support a common inflammatory dysregulation process.Citation54 As macrophages and their M1 phenotype are important in atheromatous plaque growth, their behavior in rosacea lesions could be the next step in the analysis. Recent studies show that in rosacea mouse model LL-37 cathelicidin-stimulated lesions, overexpress Desintegrin Metalloprotease ADAM-Like Decysin-1 (ADAMDEC1) protein which is also overexpressed in a culture of M1 macrophages suggesting a possible common response in both tissues.Citation55

Cutaneous Lupus Erythematosus

Cutaneous lupus erythematosus (CLE) is a skin-limited form of systemic lupus (SLE). SLE is a chronic inflammatory disease with a complex physiopathology including genetic predisposition, environmental elements such as UV light and trauma, and exposure to medications and hormones.Citation56 These factors, or some of them, interacting in a susceptible patient, can trigger an autoimmune response involving B and T lymphocytes and target-tissue damage.Citation57 CLE can occur in conjunction with SLE or independently, evolving as a unique disease without secondary tissue damage. In SLE, CVR is well known and widely accepted as a fundamental cause of morbidity and mortality in these patients.Citation58 Multiple reasons have been described, including a chronic inflammatory state associated with disease flare-ups, higher prevalence of traditional CVR factors, and treatment-associated complications.Citation59 CLE patients have a Hazard ratio (HR) of 1.31 for CVE versus general population;Citation60 in other studies, no significant differences have been found in CVE of any kind between CLE and control subjects.Citation61 CLE forms that are usually associated with SLE are more prone to show CVR features and better correlated with CVE in large studies.Citation61

Metabolic syndrome features are increased in CLE patients, and its prevalence is two times higher in these patients.Citation62 In some case-control studies, active smoking has an increased rate among CLE patients.Citation60

Many elements that are part of the plaque growing process like monocyte-recruiting, neointimal formation, and extracellular matrix production are linked with pathogenic changes observed in CLE lesions and the atheromatous process.Citation51 In CLE biopsies, a CXCL10 overexpression has been found, which leads to T cell recruitment and higher levels of Interferon-α (IFN-α) and Tumor Necrosis Factor α (TNF-α).Citation63 Some of the effects of these local and systemic cytokines are endothelial permeability and prothrombotic changes, characteristic and necessary features of atheromatosis.Citation51 Since monocytes are important in the expansion and microenvironment of the atheromatous plaque, changes in phenotype and recruiting could be an essential link between CLE and CVR.Citation64

Atopic Dermatitis

Atopic Dermatitis (AD) is a chronic inflammatory skin disease more prevalent in children. Nevertheless, the prevalence in adults has been reported to be 5% to 15%.Citation65 In all-cause mortality association studies, AD patients have a higher CVR risk than the healthy population.Citation66

Obesity, diabetes, and smoking habit are the most frequent CVR factors associated with AD.Citation67 It has been demonstrated that AD patients have an OR of 1.85 for obesity and 1.13 for diabetes. Also, as described before, arterial hypertension is more prevalent in the adult AD population.Citation68 In 2018, a systematic review and meta-analysis of 19 studies, including case-control and cohort studies, showed that myocardial infarction and other CVE are significantly higher in AD patients.Citation66 Subsequent studies showed that mainly obesity and diabetes are associated with AD diagnosis.Citation67

Early studies showed that AD patients had higher levels of platelet activation peptides than healthy subjects,Citation69 which relates to the inflammatory nature of the disease. In these studies, β-tromboglobulin, platelet factor 4, platelet-derived microparticles, and p-selectin were found to be increased in plasma of atopic patients; however, this relative “procoagulant” state never showed correlation with clinical findings.Citation69,Citation70 In newer studies, AD has been associated with autoimmune diseases like IBD, which has been associated with CVR due to a systemic inflammatory state.Citation71 A direct association between an inflammatory condition in AD and atheromatosis cannot be sustained at this point.

Other Emergent CVD-Associated Skin Diseases

Acne

It is the most common skin disease and many times a feature of systemic and metabolic diseases.Citation72 It can present as primary acne or as a part of adrenal hyperplasia, polycystic ovary syndrome, hyperandrogenism, or insulin resistance.Citation72 Some of these latter have higher cardiometabolic risk due mainly to progression to diabetes and obesity.Citation73 Besides traditional CVR factors, the chronic low-grade inflammatory response has been associated with higher CVR.Citation74

Xanthelasma Palpebrarum

Xanthelasma palpebrarum (XP) is the most common xanthoma type consisting of yellowish plaque over eyelids. It is formed by phagocytic foam cells that infiltrate perivascular territory invading superficial reticular dermis.Citation75 A clear correlation between CVR and XP diagnosis does not exist. Most of the studies are dedicated to finding the association between XP and circulating lipids profiles. In a systematic review studying 15 case-control studies gathering 854 patients with the diagnosis of XP, total cholesterol, low-density lipoproteins, ApoB, and cIMT were increased, suggesting higher indirect CVR.Citation76

Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) is characterized by wheals and angioedema for at least six weeks without an apparent stimulus.Citation77 CSU shares inflammatory features with metabolic syndrome, arising the idea of common pathogenic elements. Traditional risk factors have been described in a case-control study involving 9798 patients with chronic urticaria, who have 65% more risk of hyperlipemia and 35% more arterial hypertension versus healthy controls.Citation78 In another study, both in CSU as well as in metabolic syndrome, adipokines are augmented.Citation79 Adiponectin was decreased, and lipocalin-2 was increased in CSU patients versus control subjects.Citation80 This imbalance has been associated with a pro-inflammatory and prothrombotic metabolic state in metabolic syndrome and CSU.Citation81

Male Androgenetic Alopecia

Male androgenetic alopecia (MAG) is a common type of alopecia affecting men. Its central etiopathogenic feature is an increased sensitivity of the follicle to dihydrotestosterone; however, both inflammatory and environmental factors have contributed.Citation82 In the last 20 years, several studies have shown a correlation between MAG and CVR.Citation83 Early on, small case-control studies showed a higher prevalence of traditional and non-traditional CVR factors like obesity, diabetes, low HDL cholesterol, and cIMT.Citation84 Metabolic syndrome was five times more frequent on MAG patients and the presence of atheromatous plaques was four times more frequent than in control subjects. In a small prospective study, 50% of MAG patients fulfilled the criteria for metabolic syndrome versus 15% in the control group.Citation84 Possible explanations for these findings are related to testosterone levels and metabolic changes associated with these increased levels.Citation85

Calciphylaxis

This is a life-threatening condition characterized by calcification of microvessels in the subcutaneous tissue and dermis. It presents preferably in end-stage renal disease patients with a poor prognosis and life expectancy of about one year.Citation86 Given this noticeably short survival, long-standing outcomes as cardiometabolic complications are challenging to assess.Citation87 Through an indirect connection, calciphylaxis has inflammatory features stimulated by the deposit of calcium hydroxyapatite in between muscular cells, triggering local inflammatory and deregulatory responses.Citation88 This dysregulation could interact with diseases like diabetes which facilitate activation of transcriptional factor Runt-related transcription factor 2 (RUNX2), leading to calcium deposit in muscular and intimal vascular layers, with subsequent endothelial disfunction and local thrombosis.Citation89

Seborrheic Dermatitis

Seborrheic Dermatitis (SD) is a chronic inflammatory disease characterized by desquamative inflammatory lesions with frequent recurrences and remissions.Citation90 As an inflammatory disease, it has been associated with metabolic disturbances. Obese and metabolic-dysregulated patients have a higher prevalence of SD between their comorbidities.Citation91 Also, SD patients had significantly lower HDL levels and a higher rate of relatives with arterial hypertension, suggesting a relation between both diseases sustained by a higher prevalence of CVR.Citation92

Vitiligo

Vitiligo is a depigmenting autoimmune disease. Recent studies suggest a subset of vitiligo patients, those with more chronic and severe diseases, are at higher risk of developing dyslipidemia and atherosclerosis, with the potential increase of CVR.Citation93,Citation94 Interestingly, the use of narrowband UVB phototherapy treatment correlated with a significant decrease in CV and cerebrovascular events.Citation95 Also, simvastatin, a statin drug, has been tried as a vitiligo treatment, showing beneficial effects, attributed to its antioxidant and immunomodulating effect.Citation96 Despite these findings, further studies are needed.

Discussion

Many inflammatory conditions are associated with CVR. In autoimmune diseases like rheumatoid arthritis, spondylarthritis, and psoriatic arthritis, this is the first cause of mortality and morbidity. Among physio-pathological explanations are chronic inflammation, higher prevalence of traditional CVR factors, and specific pathogenic features that participate in the disease and the atheromatous process. It is uncommon for dermatologists to assess and treat CVR factors in their patients. Many skin diseases have localized involvement and do not affect other organs or tissues. Maybe the most emblematic case is psoriasis, where cardiovascular mortality has been well documented and widely accepted as an important consequence of the disease. Here, we presented skin conditions highlighting those traditionally associated with CVD and mentioning possible elements in other emerging diseases in which CVR could rise. Some disorders seem to directly relate to their pathogenic processes and the atheromatous plaque formation that is measurable both in plasma and tissue. These include common pathway activation and inflammatory cytokine overexpression, higher prevalence of traditional CVR factors, and systemic chronic inflammatory state. Other emerging and less studied skin conditions sometimes show epidemiological analysis positively correlating with CVD, in which, beyond chronic inflammation, there is no other molecular plasma or tissue link between skin disease and atheromatosis. Some systemic skin diseases are susceptible to the metabolic state like psoriasis and hidradenitis suppurativa; cardiovascular risk is higher and associated with the inflammatory condition of the disease. In these cases, it is essential to pursue remission as a target to cardiovascular risk reduction, but also traditional risk factors must also be assessed thoroughly. In other diseases, where the association is linked mainly by local or systemic inflammatory state, exhaustive treatment strategies must be implemented; moreover, when the presence of the skin disease is expected to be for life. This low-grade inflammatory state has been frequently related to the atheromatosis process, primarily associated with chronic systemic inflammatory diseases and altered metabolic states. Still, we cannot forget that dermatologic inflammatory conditions are sometimes locally detected but systemic and chronic and need to be treated as a part of the integral management of our patients.

Conclusions

Re acknowledging traditional and emerging related skin diseases should prompt dermatologists, cardiologists, and primary care providers to include and manage modifiable risk factors, with particular consideration in these patients. It is imperative to achieve the best possible control of the related skin conditions in patients with a higher baseline CVR, mainly in those traditionally associated diseases (). Finally, in skin diseases with a shared molecular mechanism between skin damage and atheromatous process formation, achieving remission of the skin disease could be significant in CVD risk management. More studies are needed, especially on emerging CVD-associated skin diseases, to understand better common pathogenic pathways that could lead to new treatment strategies.

Table 2 CVD-Associated Skin Diseases

Author Contributions

All authors contributed to data analysis, drafting, or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • Perk J. The 2016 version of the European Guidelines on Cardiovascular Prevention. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):9–10. doi:10.1093/ehjcvp/pvw030
  • Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis. 2004;176(1):1–19. doi:10.1016/j.atherosclerosis.2003.11.022
  • Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2020;3:e58–e70. doi:10.1016/S2665-9913(20)30221-6
  • Piranavan P, Perl A. Management of cardiovascular disease in patients with systemic lupus erythematosus. Expert Opin Pharmacother. 2020;21(13):1617–1628. doi:10.1080/14656566.2020.1770227
  • Bulger DA, Minhas S, Asbeutah AA, et al. Chronic systemic inflammatory skin disease as a risk factor for cardiovascular disease. Curr Probl Cardiol. 2021;46(5):100799. doi:10.1016/j.cpcardiol.2021.100799
  • Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. doi:10.3389/fphar.2020.00117
  • Woo YR, Park CJ, Kang H, Kim JE. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic. Int J Mol Sci. 2020;21(19):7041. doi:10.3390/ijms21197041
  • Lee MS, Yeh YC, Chang YT, Lai MS. All-cause and cause-specific mortality in patients with psoriasis in Taiwan: a nationwide population-based study. J Invest Dermatol. 2017;137(7):1468–1473. doi:10.1016/j.jid.2017.01.036
  • Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
  • Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695–1706. doi:10.1111/jdv.16273
  • Phan K, Lee G, Fischer G. Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis. Pediatr Dermatol. 2020;37(4):661–669. doi:10.1111/pde.14208
  • Hu MY, Yang Q, Zheng J. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms. Clin Exp Dermatol. 2020;45(7):836–840. doi:10.1111/ced.14327
  • Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650–656 e653. doi:10.1016/j.jaad.2017.06.028
  • Abbas A, Gregersen I, Holm S, et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015;46(3):793–799. doi:10.1161/STROKEAHA.114.006516
  • Lee YH, Cui LH, Shin MH, et al. Associations between carotid intima-media thickness, plaque and cardiovascular risk factors. J Prev Med Public Health. 2006;39(6):477–484.
  • Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis, and atherothrombosis. Mediators Inflamm. 2019;2019:7434376. doi:10.1155/2019/7434376
  • Goecke A, Karsulovic C, Guerrero J, Tempio F, Lopez M. SAT0004 INCREASED M1 INFLAMMATORY PHENOTYPE of CIRCULATING MONOCYTES is ASSOCIATED with HISTORY of CARDIOVASCULAR EVENTS in RA PATIENTS. BMJ Publishing Group Ltd; 2020.
  • Wang Y, Edelmayer R, Wetter J, et al. Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation. Sci Rep. 2019;9(1):5310. doi:10.1038/s41598-019-41655-7
  • Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and non-alcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184–6223. doi:10.3390/ijms15046184
  • Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am. 2018;102(1):13–33. doi:10.1016/j.mcna.2017.08.004
  • Chen Y, Tian J, Tian X, et al. Adipose tissue dendritic cells enhances inflammation by prompting the generation of Th17 cells. PLoS One. 2014;9(3):e92450. doi:10.1371/journal.pone.0092450
  • Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6(3):e18227. doi:10.1371/journal.pone.0018227
  • Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010;10(7):501–513. doi:10.1038/nri2787
  • Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668. doi:10.3389/fimmu.2018.01668
  • Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular comorbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15(1):45–50. doi:10.1007/s40257-013-0052-6
  • Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250. doi:10.1001/archdermatol.2012.2502
  • Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. doi:10.1016/j.jaad.2016.07.042
  • von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
  • Pina Vegas L, Le Corvoisier P, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology. 2021. doi:10.1093/rheumatology/keab522
  • Poizeau F, Nowak E, Kerbrat S, et al. association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. jama dermatol. 2020;156(11):1208–1215. doi:10.1001/jamadermatol.2020.2977
  • Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and metabolic syndrome – systematic review and adjusted meta‐analysis. Int J Dermatol. 2019;58(10):1112–1117. doi:10.1111/ijd.14500
  • Tzellos T, Zouboulis CC. Review of Comorbidities of Hidradenitis Suppurativa: implications for Daily Clinical Practice. Dermatol Ther (Heidelb). 2020;10(1):63–71. doi:10.1007/s13555-020-00354-2
  • Fauconier M, Reguiai Z, Barbe C, et al. Association between hidradenitis suppurativa and spondyloarthritis. Joint Bone Spine. 2018;85(5):593–597. doi:10.1016/j.jbspin.2017.09.005
  • Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Women’s Dermatol. 2019;5(5):330–334. doi:10.1016/j.ijwd.2019.06.026
  • De Vita V, Hansen PR. Interleukin-32 may contribute to increased risk of cardiovascular disease in patients with hidradenitis suppurativa. Atherosclerosis. 2017;267:175. doi:10.1016/j.atherosclerosis.2017.10.001
  • Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2020;35:50–61. doi:10.1111/jdv.16677
  • Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2016;152(4):429. doi:10.1001/jamadermatol.2015.6264
  • Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta‐analysis. Clin Exp Dermatol. 2019;44(4):e126–e132. doi:10.1111/ced.13922
  • Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GBE. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142–1155. doi:10.1111/bjd.14024
  • González-López MA, Hernández JL, Lacalle M, et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75(2):329–335. doi:10.1016/j.jaad.2016.03.025
  • Chen W-T, Chi -C-C. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease. JAMA Dermatol. 2019;155(9):1022. doi:10.1001/jamadermatol.2019.0891
  • Moltó A, Nikiphorou E. Comorbidities in Spondyloarthritis. Frontiers in Medicine. 2018;5:5. doi:10.3389/fmed.2018.00005
  • Wollina U. Is rosacea a systemic disease? Clin Dermatol. 2019;37(6):629–635. doi:10.1016/j.clindermatol.2019.07.032
  • Molina MT, Patogenia de la R. Actualización Expresión Anormal de un Péptido Antimicrobiano, la Catelicidina, Estrés Oxidativo y Niveles de Ferritina. Revista Chilena de Dermatologia. 2009;25(1):57–61.
  • Ahn CS, Huang WW. Rosacea Pathogenesis. Dermatol Clin. 2018;36(2):81–86. doi:10.1016/j.det.2017.11.001
  • Li Y, Guo L, Hao D, Li X, Wang Y, Jiang X. Association between Rosacea and Cardiovascular Diseases and Related Risk Factors: a Systematic Review and Meta-Analysis. Biomed Res Int. 2020;2020:1–11.
  • Stefanadi EC, Dimitrakakis G, Antoniou C-K, et al. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetol Metab Syndr. 2018;10(1). doi:10.1186/s13098-018-0311-z.
  • Hayran Y, Lay I, Mocan MC, Bozduman T, Ersoy-Evans S. Vascular endothelial growth factor gene polymorphisms in patients with rosacea: a case-control study. J Am Acad Dermatol. 2019;81(2):348–354. doi:10.1016/j.jaad.2019.03.055
  • Chen Y, Dawes PT, Packham JC, Mattey DL. Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J Rheumatol. 2011;38(5):802–809. doi:10.3899/jrheum.101095
  • Akin Belli A, Altun I. Assessment of Framingham risk score and systemic coronary risk evaluation in rosacea patients. Dermatologica Sinica. 2017;35(3):127–130. doi:10.1016/j.dsi.2017.03.006
  • Herrero-Fernandez B, Gomez-Bris R, Somovilla-Crespo B, Gonzalez-Granado JM. Immunobiology of Atherosclerosis: a Complex Net of Interactions. Int J Mol Sci. 2019;20(21):5293. doi:10.3390/ijms20215293
  • Alford MA, Baquir B, Santana FL, Haney EF, Hancock REW. Cathelicidin Host Defense Peptides and Inflammatory Signaling: striking a Balance. Front Microbiol. 2020;11:1902. doi:10.3389/fmicb.2020.01902
  • Chen X, Zou X, Qi G, et al. Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. Cell Physiol Biochem. 2018;47(3):1060–1073. doi:10.1159/000490183
  • Edfeldt K, Agerberth B, Rottenberg ME, et al. Involvement of the Antimicrobial Peptide LL-37 in Human Atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(7):1551–1557. doi:10.1161/01.ATV.0000223901.08459.57
  • Liu T, Deng Z, Xie H, et al. ADAMDEC1 promotes skin inflammation in rosacea via modulating the polarization of M1 macrophages. Biochem Biophys Res Commun. 2020;521(1):64–71. doi:10.1016/j.bbrc.2019.10.073
  • Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404. doi:10.1016/j.berh.2013.07.008
  • Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216–229. doi:10.23736/S0392-0488.18.05929-1
  • Ahlehoff O, Wu JJ, Raunso J, et al. Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: a Danish nationwide cohort study. Lupus. 2017;26(13):1435–1439. doi:10.1177/0961203317716306
  • Guo LN, Nambudiri VE. Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. Clin Rheumatol. 2020;40:491–499. doi:10.1007/s10067-020-05257-3
  • Hesselvig JH, Ahlehoff O, Dreyer L, Gislason G, Kofoed K. Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. Lupus. 2017;26(1):48–53. doi:10.1177/0961203316651739
  • Singh AG, Crowson CS, Singh S, et al. Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: a Population-Based Cohort Study. Arthritis Care Res. 2016;68(11):1664–1670. doi:10.1002/acr.22892
  • Akarsu S, Ozbagcivan O, Semiz F, Aktan S. High Prevalence of Metabolic Syndrome in Patients with Discoid Lupus Erythematosus: a Cross-Sectional, Case-Control Study. J Immunol Res. 2017;2017:1–8. doi:10.1155/2017/3972706
  • Dey-Rao R, Sinha AA. Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation. Genomics. 2015;105(2):90–100. doi:10.1016/j.ygeno.2014.11.004
  • Masek-Hammerman K, Peeva E, Ahmad A, et al. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus ery. Clin Exp Immunol. 2016;183(2):258–270. doi:10.1111/cei.12705
  • Andersen YMF, Egeberg A, Skov L, Thyssen JP. Comorbidities of Atopic Dermatitis: beyond Rhinitis and Asthma. Curr Dermatol Rep. 2017;6(1):35–41. doi:10.1007/s13671-017-0168-7
  • Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol. 2019;143(5):1821–1829. doi:10.1016/j.jaci.2018.11.030
  • Ali Z, Ulrik Charlotte S, Agner T, Thomsen Simon F. Association between Atopic Dermatitis and the Metabolic Syndrome: a Systematic Review. Dermatology. 2018;234(3–4):79–85. doi:10.1159/000491593
  • Kwa MC, Silverberg JI. Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Comorbidities in US Adults: analysis of Nationwide Inpatient Sample Data. Am J Clin Dermatol. 2017;18(6):813–823. doi:10.1007/s40257-017-0293-x
  • Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis. Clin Immunol. 2009;131(3):495–500. doi:10.1016/j.clim.2009.01.006
  • Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated Platelet Activation in Patients with Atopic Dermatitis and Psoriasis: increased Plasma Levels of β-Thromboglobulin and Platelet Factor 4. Allergology Int. 2008;57(4):391–396. doi:10.2332/allergolint.O-08-537
  • Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–151. doi:10.1016/j.anai.2019.04.020
  • Zouboulis CC. Acne as a chronic systemic disease. Clin Dermatol. 2014;32(3):389–396. doi:10.1016/j.clindermatol.2013.11.005
  • Hamjane N, Benyahya F, Nourouti NG, Mechita MB, Barakat A. Cardiovascular diseases and metabolic abnormalities associated with obesity: what is the role of inflammatory responses? A systematic review. Microvasc Res. 2020;131:104023. doi:10.1016/j.mvr.2020.104023
  • Karapinar T, Polat M, Bugdayci G. Evaluation of subclinical atherosclerosis in Turkish patients with acne vulgaris receiving systemic isotretinoin. Dermatol Ther. 2020;33(3):e13307. doi:10.1111/dth.13307
  • Nair P, Singhal R. Xanthelasma palpebrarum – a brief review. Clin Cosmet Investig Dermatol. 2017;11:1–5. doi:10.2147/CCID.S130116
  • Chang H-C, Sung C-W, Lin M-H. Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):596–605. doi:10.1016/j.jaad.2019.08.082
  • Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol. 2016;174(5):996–1004. doi:10.1111/bjd.14470
  • Chung S-D, Wang K-H, Tsai M-C, Lin H-C, Chen C-H. Hyperlipidemia is associated with chronic urticaria: a Population-Based Study. PLoS One. 2016;11(3):e0150304. doi:10.1371/journal.pone.0150304
  • Adamczyk K, Wcisło-Dziadecka D, Zbiciak-Nylec M, Brzezińska-Wcisło L, Brzoza Z. Does adiponectin play a role in the pathogenesis of chronic spontaneous urticaria? Central Eur J Immunol. 2020;45(1):56–59. doi:10.5114/ceji.2020.94678
  • Trinh HKT, Pham DL, Ban G-Y, Lee H-Y, Park H-S, Ye Y-M. Altered Systemic Adipokines in Patients with Chronic Urticaria. Int Arch Allergy Immunol. 2016;171(2):102–110. doi:10.1159/000452626
  • Rogala B, Bozek A, Glück J, Rymarczyk B, Jarzab J, Maurer M. Coexistence of Angioedema Alone with Impaired Glucose Tolerance. Int Arch Allergy Immunol. 2014;165(4):265–269. doi:10.1159/000371421
  • Heilmann-Heimbach S, Hochfeld LM, Henne SK, Nothen MM. Hormonal regulation in male androgenetic alopecia-Sex hormones and beyond: evidence from recent genetic studies. Exp Dermatol. 2020;29:814–827. doi:10.1111/exd.14130
  • Yamada T, Hara K, Umematsu H, Kadowaki T. Male pattern baldness and its association with coronary heart disease: a meta-analysis. BMJ Open. 2013;3(4):e002537. doi:10.1136/bmjopen-2012-002537
  • Ertas R, Orscelik O, Kartal D, et al. Androgenetic alopecia as an indicator of metabolic syndrome and cardiovascular risk. Blood Press. 2015;25(3):141–148. doi:10.3109/08037051.2015.1111021
  • Li H, Kong XB, Zhang HL, Wu J. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular diseases. J Sex Med. 2011;8(4):1260. doi:10.1111/j.1743-6109.2010.01876.x
  • Nigwekar SU, Ingelfinger JR, Thadhani R, Brandenburg VM. Calciphylaxis. N Eng J Med. 2018;378(18):1704–1714. doi:10.1056/NEJMra1505292
  • Bover J, Urena-Torres P, Gorriz JL, et al. Cardiovascular calcifications in chronic kidney disease: potential therapeutic implications. Nefrologia. 2016;36(6):597–608. doi:10.1016/j.nefro.2016.05.023
  • Urena-Torres PA, Floege J, Hawley CM, et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant. 2013;28(1):146–152. doi:10.1093/ndt/gfs356
  • Toth A, Balogh E, Jeney V. Regulation of Vascular Calcification by Reactive Oxygen Species. Antioxidants. 2020;9(10). doi:10.3390/antiox9100963
  • Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):343–351. doi:10.1016/j.clindermatol.2013.01.001
  • Imamoglu B, Hayta SB, Guner R, Akyol M, Ozcelik S. Metabolic syndrome may be an important comorbidity in patients with seborrheic dermatitis. Arch Med Sci Atheroscler Dis. 2016;1(1):e158–e161. doi:10.5114/amsad.2016.65075
  • Linder D, Dreiher J, Zampetti A, Sampogna F, Cohen AD. Seborrheic dermatitis and hypertension in adults: a cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28(11):1450–1455. doi:10.1111/jdv.12310
  • Azzazi Y, Mostafa WZ, Sayed KS, et al. Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: a hospital-based, case-control study. Pigment Cell Melanoma Res. 2021;34(3):598–604. doi:10.1111/pcmr.12941
  • Namazi N, Amani M, Haghighatkhah HR, Noori E, Abdollahimajd F. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo: a real association or a coincidence? Dermatol Ther. Mar. 2021;34(2):e14803.
  • Bae JM, Kim YS, Choo EH, et al. Both cardiovascular and cerebrovascular events are decreased following long-term narrowband ultraviolet B phototherapy in patients with vitiligo: a propensity score matching analysis. J Eur Acad Dermatol Venereol. 2021;35(1):222–229. doi:10.1111/jdv.16830
  • Verma D, Hussain K, Namiq KS, et al. Vitiligo: the Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator. Cureus. 2021;13(3):e14029. doi:10.7759/cureus.14029